ArticleClinical and translational radiation oncology2027
PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy-a retrospective single-centre experience.
Article in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anal squamous cell carcinoma (ASCC) is rare, and optimal treatment for patients unsuitable for definitive chemoradiotherapy remains undefined. This study describes PACTUS (Palliative Anal Cancer Treatment Uppsala Style), a two-week radiotherapy regimen designed for symptom relief and potentially durable local control. Methods: We retrospectively reviewed consecutive patients with ASCC treated with palliative-intent radiotherapy at Uppsala University Hospital (2017-2025). The principal cohort received PACTUS (40 Gy in 10 fractions). Patients treated with Short-course or Quad Shot were included as contextual case series. Treatment selection was based on patient fitness, anticipated tolerance, prognosis, logistics, and patient preference. Overall survival (OS) was measured from radiotherapy initiation. Clinical response, symptom outcomes, and adverse effects were summarized using evaluable denominators. Results: Of 735 patients treated for ASCC, 35 (4.7%) received palliative-intent radiotherapy: 28 received PACTUS, 4 Short-course, and 3 Quad Shot. The median age was 80 years (range, 60-97), 25 (71%) were women, and 30 (86%) had an ECOG performance status ≥3. Elective nodal irradiation was delivered to 24/28 patients in PACTUS. The median OS in PACTUS cohort was 30 months. At the data cut-off (April 2, 2026), 20 patients had died: 14/28 (50%) in PACTUS, 4/4 (100%) in Short-course, and 2/3 (67%) in Quad Shot. Median follow-up among surviving patients was 20 months (range, 4-71 months). Clinical response was evaluable in 15/35 (43%) patients and symptom outcomes in 13/35 (37%); therefore, these findings were not considered representative of the full cohort. Toxicity was not collected systematically or graded prospectively. Conclusions: PACTUS was feasible in this selected cohort of predominantly elderly and comorbid patients and warrants prospective evaluation. However, because treatment selection was guided by patient fitness and anticipated treatment tolerance, comparisons between the alternative regimens are descriptive only and cannot establish comparative effectiveness or a survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.